Full Breakdown
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million
4/9/2026, 5:48:27 AM
Strategic Acquisition in Biopharmaceuticals
Everest Medicines, a Shanghai-based biopharmaceutical company, has announced a significant acquisition, agreeing to spend US$250 million to purchase Hasten Biopharmaceuticals, a Singapore-based firm. This acquisition includes the assumption of a US$148.8 million shareholder loan from Hasten's parent company. The deal, disclosed in a stock exchange filing, positions Everest to expand its portfolio of chronic-disease treatments across the Asia-Pacific region, as Hasten holds rights to 14 such treatments.
Financial Overview and Valuation
An independent valuation estimated Hasten's equity value at approximately US$320 million as of March 31, indicating that Everest is acquiring the company at a roughly 22 percent discount. Hasten Biopharmaceuticals is recognized for its 120-member team that specializes in addressing cardiovascular, renal, and metabolic diseases. This acquisition aligns with Everest's strategy to broaden the reach of its commercialized drugs beyond mainland China.
Broader Trends in Chinese Biotech
The acquisition of Hasten is part of a larger trend in China's biopharmaceutical sector, which has experienced a surge in deal-making. Sovereign wealth funds from Singapore and the United Arab Emirates are increasingly investing alongside Chinese state-backed investors in next-generation drug developers. Notably, cross-border out-licensing by Chinese drugmakers reached a record US$60 billion in the first quarter of the year, driven by heightened interest from multinational pharmaceutical companies in early-stage assets.
Official Statements & Responses
Everest Medicines emphasized that this acquisition would bolster its capabilities in the Asia-Pacific market, enhancing its portfolio of chronic-disease treatments. The company stated, "This strategic move will support our mission to deliver innovative therapies to patients in need."
Criticism & Opposition
While the acquisition is seen as a positive step for Everest Medicines, some industry analysts express caution regarding the sustainability of such rapid growth in the Chinese biotech sector. Critics argue that the influx of capital may lead to inflated valuations and unsustainable business practices, potentially jeopardizing long-term stability in the market.
What's Next
Following the acquisition, Everest Medicines is expected to focus on integrating Hasten's operations and leveraging its expertise to enhance its product offerings. The company aims to capitalize on the growing demand for chronic-disease treatments in the Asia-Pacific region, positioning itself as a key player in the evolving biopharmaceutical landscape.
